PepGen Inc. (NASDAQ:PEPG) shows promise with its DM1 program and positive Phase 1 data. BofA raised the price target to $3, noting the company's potential but also highlighting its developmental timeline and uncertainties.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing